Martin Haluzik

List of Publications by Year
in descending order

191	14,848	50276	19190
papers	citations	46 h-index	118 g-index

193	193	193	18888
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Adipose tissue immune cells in obesity, type 2 diabetes mellitus and cardiovascular diseases. Journal of Endocrinology, 2022, 252, R1-R22.	2.6	23
2	An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus. Expert Opinion on Drug Safety, 2022, 21, 349-361.	2.4	4
3	The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia. Current Atherosclerosis Reports, 2022, 24, 13-21.	4.8	7
4	Gene Profile of Adipose Tissue of Patients with Pheochromocytoma/Paraganglioma. Biomedicines, 2022, 10, 586.	3.2	3
5	Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the <scp>PIONEER</scp> phase 3 programme. Diabetes, Obesity and Metabolism, 2022, 24, 1338-1350.	4.4	12
6	Mitochondrially targeted tamoxifen alleviates markers of obesity and type 2 diabetes mellitus in mice. Nature Communications, 2022, 13, 1866.	12.8	8
7	Adiponectin, A-FABP and FGF-19 Levels in Women with Early Diagnosed Gestational Diabetes

. Journal of Clinical Medicine, 2022, 11, 2417. | 2.4 | 5 |
8	Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Advances in Therapy, 2022, 39, 2452-2467.	2.9	58
9	Therapieintensivierung bei mit basalunterstÃ¼tzter oraler Therapie (BOT) unkontrolliertem Typ-2-Diabetes: Subanalyse der SoliMix-Studie bei Teilnehmern in Europa. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
10	A plant-based meal affects thalamus perfusion differently than an energy- and macronutrient-matched conventional meal in men with type 2 diabetes, overweight/obese, and healthy men: A three-group randomized crossover study. Clinical Nutrition, 2021, 40, 1822-1833.	5.0	7
11	Effect of Complex Weight-Reducing Interventions on Rhythm Control in Obese Individuals with Atrial Fibrillation Following Catheter Ablation: A Study Protocol. Advances in Therapy, 2021, 38, 2007-2016.	2.9	3
12	Different Expression of Mitochondrial and Endoplasmic Reticulum Stress Genes in Epicardial Adipose Tissue Depends on Coronary Atherosclerosis. International Journal of Molecular Sciences, 2021, 22, 4538.	4.1	5
13	Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166148.	3.8	14
14	Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress. International Journal of Molecular Sciences, 2021, 22, 10606.	4.1	15
15	In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. International Journal of Molecular Sciences, 2021, 22, 11513.	4.1	20
16	Endoscopic Treatment of Obesity and Nutritional Aspects of Bariatric Endoscopy. Nutrients, 2021, 13, 4268.	4.1	8
17	Association of Serum Bilirubin and Functional Variants of Heme Oxygenase 1 and Bilirubin UDP-Glucuronosyl Transferase Genes in Czech Adult Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants, 2021, 10, 2000.	5.1	6
18	Influence of glucometric â€˜dynamicalâ€™ variables on duodenalâ€jejunal bypass liner (DJBL) anthropometric and metabolic outcomes. Diabetes/Metabolism Research and Reviews, 2020, 36, e3287.	4.0	3

#	Article	IF	Citations
19	A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100â€‰units/mL at 26â€‰weeks: DUAL VIII, a randomized trial designed to resemble clinical practice. Diabetes, Obesity and Metabolism, 2020, 22, 873-878.	4.4	6
20	Dysregulation of epicardial adipose tissue in cachexia due to heart failure: the role of natriuretic peptides and cardiolipin. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1614-1627.	7.3	24
21	Spontaneous delivery is associated with increased endothelial activity in cord blood compared to elective cesarean section. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 251, 229-234.	1.1	3
22	The Influence of Cyclical Ketogenic Reduction Diet vs. Nutritionally Balanced Reduction Diet on Body Composition, Strength, and Endurance Performance in Healthy Young Males: A Randomized Controlled Trial. Nutrients, 2020, 12, 2832.	4.1	14
23	Subclinical Inflammation and Adipose Tissue Lymphocytes in Pregnant Females With Gestational Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3892-e3902.	3.6	11
24	Lipid Profiling in Epicardial and Subcutaneous Adipose Tissue of Patients with Coronary Artery Disease. Journal of Proteome Research, 2020, 19, 3993-4003.	3.7	7
25	Differential glycaemic control with basal insulin glargine 300 <scp>U/mL</scp> versus degludec 100 <scp>U/mL</scp> according to kidney function in type 2 diabetes: A subanalysis from the <scp>BRIGHT</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1369-1377.	4.4	26
26	Pheochromocytoma With Adrenergic Biochemical Phenotype Shows Decreased GLP-1 Secretion and Impaired Glucose Tolerance. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1878-1887.	3.6	13
27	Synergistic effect of leptin and lipidized PrRP on metabolic pathways in ob/ob mice. Journal of Molecular Endocrinology, 2020, 64, 77-90.	2.5	11
28	The possible role of endocrine dysfunction of adipose tissue in gestational diabetes mellitus. Minerva Endocrinologica, 2020, 45, 228-242.	1.8	7
29	The effect of dicarbonyl stress on the development of kidney dysfunction in metabolic syndrome â€“ a transcriptomic and proteomic approach. Nutrition and Metabolism, 2019, 16, 51.	3.0	10
30	The number and phenotype of myocardial and adipose tissue CD68+ cells is associated with cardiovascular and metabolic disease in heart surgery patients. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 946-955.	2.6	13
31	The relationship of mitochondrial dysfunction and the development of insulin resistance in Cushingâ€™s syndrome . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1459-1471.	2.4	3
32	Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 596-605.	11.4	46
33	PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 1724-1732.	8.6	227
34	Dendritic Cells in Subcutaneous and Epicardial Adipose Tissue of Subjects with Type 2 Diabetes, Obesity, and Coronary Artery Disease. Mediators of Inflammation, 2019, 2019, 1-7.	3.0	20
35	Neudesin in obesity and type 2 diabetes mellitus: the effect of acute fasting and weight reducing interventions . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 423-430.	2.4	8
36	Coronary Artery Disease Is Associated with an Increased Amount of T Lymphocytes in Human Epicardial Adipose Tissue. Mediators of Inflammation, 2019, 2019, 1-9.	3.0	14

#	Article	IF	Citations
37	Influence of Duodenalâ€“Jejunal Implantation on Glucose Dynamics: A Pilot Study Using Different Nonlinear Methods. Complexity, 2019, 2019, 1-10.	1.6	1
38	A Plant-Based Meal Stimulates Incretin and Insulin Secretion More Than an Energy- and Macronutrient-Matched Standard Meal in Type 2 Diabetes: A Randomized Crossover Study. Nutrients, 2019, 11, 486.	4.1	24
39	Minor lipids profiling in subcutaneous and epicardial fat tissue using LC/MS with an optimized preanalytical phase. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1113, 50-59.	2.3	9
40	FGF21 Levels in Pheochromocytoma/Functional Paraganglioma. Cancers, 2019, 11, 485.	3.7	2
41	Metabolomics Based on MS in Mice with Diet-Induced Obesity and Type 2 Diabetes Mellitus: the Effect of Vildagliptin, Metformin, and Their Combination. Applied Biochemistry and Biotechnology, 2019, 188, 165-184.	2.9	11
42	Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of Î²-amyloid pathology. Neuropharmacology, 2019, 144, 377-387.	4.1	52
43	A Plant-Based Meal Increases Gastrointestinal Hormones and Satiety More Than an Energy- and Macronutrient-Matched Processed-Meat Meal in T2D, Obese, and Healthy Men: A Three-Group Randomized Crossover Study. Nutrients, 2019, 11, 157.	4.1	39
44	The coâ€formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled metaâ€analysis of phase III studies in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1585-1592.	4.4	11
45	Gut as an emerging organ for the treatment of diabetes: focus on mechanism of action of bariatric and endoscopic interventions. Journal of Endocrinology, 2018, 237, R1-R17.	2.6	23
46	Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study. Nutrition and Diabetes, 2018, 8, 5.	3.2	15
47	Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: the effect of weight reduction and realimentation. Nutrition and Diabetes, 2018, 8, 21.	3.2	52
48	Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries. Diabetes Therapy, 2018, 9, 727-741.	2.5	5
49	Characterization of Artifact Influence on the Classification of Glucose Time Series Using Sample Entropy Statistics. Entropy, 2018, 20, 871.	2.2	12
50	The role of obesity and adipose tissue dysfunction in gestational diabetes mellitus. Journal of Endocrinology, 2018, 238, R63-R77.	2.6	41
51	Endothelial Microvesicles and Soluble Markers of Endothelial Injury in Critically Ill Newborns. Mediators of Inflammation, 2018, 2018, 1-8.	3.0	15
52	Intermittent Fasting and Prevention of Diabetic Retinopathy: Where Do We Go From Here?. Diabetes, 2018, 67, 1745-1747.	0.6	12
53	The Role of Inflammation in Epicardial Adipose Tissue in Heart Diseases. Current Pharmaceutical Design, 2018, 24, 297-309.	1.9	15
54	The effects of liraglutide in mice with diet-induced obesity studied by metabolomics. Journal of Endocrinology, 2017, 233, 93-104.	2.6	23

#	Article	IF	Citations
55	Lymphocytes and macrophages in adipose tissue in obesity: markers or makers of subclinical inflammation?. Protoplasma, 2017, 254, 1219-1232.	2.1	47
56	Effect of continuous exenatide infusion on cardiac function and periâ€operative glucose control in patients undergoing cardiac surgery: A singleâ€blind, randomized controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 1818-1822.	4.4	22
57	A novel approach to glycemic control in type 2 diabetes mellitus, partial jejunal diversion: pre-clinical to clinical pathway. BMJ Open Diabetes Research and Care, 2017, 5, e000431.	2.8	7
58	Angiopoietin-like protein 6 in patients with obesity, type 2 diabetes mellitus, and anorexia nervosa: The influence of very low-calorie diet, bariatric surgery, and partial realimentation. Endocrine Research, 2017, 42, 22-30.	1.2	9
59	Salsalate ameliorates metabolic disturbances by reducing inflammation in spontaneously hypertensive rats expressing human C-reactive protein and by activating brown adipose tissue in nontransgenic controls. PLoS ONE, 2017, 12, e0179063.	2.5	6
60	Impact of novel palmitoylated prolactin-releasing peptide analogs on metabolic changes in mice with diet-induced obesity. PLoS ONE, 2017, 12, e0183449.	2.5	35
61	Leader 8: Type 2 Diabetes Patients: A Comparison of Baseline Characteristics of Eastern and Western European Participants with Established Cardiovascular Disease in the LEADER Trial. Journal of Diabetes & Metabolism, 2016, 07, .	0.2	0
62	Hyperbilirubinemia Protects against Aging-Associated Inflammation and Metabolic Deterioration. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	4.0	51
63	Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination. Molecular and Cellular Endocrinology, 2016, 431, 88-100.	3.2	34
64	LEADER-4. Journal of Hypertension, 2016, 34, 1140-1150.	0.5	13
65	Endocrine effects of duodenalâ€“jejunal exclusion in obese patients with type 2 diabetes mellitus. Journal of Endocrinology, 2016, 231, 11-22.	2.6	36
66	Mutated Huntingtin Causes Testicular Pathology in Transgenic Minipig Boars. Neurodegenerative Diseases, 2016, 16, 245-259.	1.4	22
67	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 311-322.	27.0	5,070
68	Metabolomic profiling of urinary changes in mice with monosodium glutamate-induced obesity. Analytical and Bioanalytical Chemistry, 2016, 408, 567-578.	3.7	26
69	Twiceâ€daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulinâ€naÃ¯ve adults with Type 2 diabetes. Diabetic Medicine, 2016, 33, 497-505.	2.3	38
70	The role of bile acids in metabolic regulation. Journal of Endocrinology, 2016, 228, R85-R96.	2.6	104
71	Palmitoylated PrRP analog decreases body weight in DIO rats but not in ZDF rats. Journal of Endocrinology, 2016, 229, 85-96.	2.6	19
72	Urine Levels of Phthalate Metabolites and Bisphenol A in Relation to Main Metabolic Syndrome Components: Dyslipidemia, Hypertension and Type 2 Diabetes. A pilot study. Central European Journal of Public Health, 2016, 24, 297-301.	1.1	26

#	Article	IF	Citations
73	The Possible Role of mRNA Expression Changes of GH/IGF-1/Insulin Axis Components in Subcutaneous Adipose Tissue in Metabolic Disturbances of Patients With Acromegaly. Physiological Research, 2016, 65, 493-503.	0.9	2
74	The duodenal-jejunal bypass liner (EndoBarrierÂ®) for the treatment of type 2 diabetes mellitus in obese patients â€“ efficacy and factors predicting optimal effects. Gastroenterologie A Hepatologie, 2016, 70, 491-499.	0.1	0
75	Anorexigenic Lipopeptides Ameliorate Central Insulin Signaling and Attenuate Tau Phosphorylation in Hippocampi of Mice with Monosodium Glutamate-Induced Obesity. Journal of Alzheimer's Disease, 2015, 45, 823-835.	2.6	39
76	Novel lipidized analogs of prolactin-releasing peptide have prolonged half-lives and exert anti-obesity effects after peripheral administration. International Journal of Obesity, 2015, 39, 986-993.	3.4	51
77	Perioperative Tight Glucose Control Reduces Postoperative Adverse Events in Nondiabetic Cardiac Surgery Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3081-3089.	3.6	67
78	Strategy for NMR metabolomic analysis of urine in mouse models of obesityâ€" from sample collection to interpretation of acquired data. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 225-235.	2.8	17
79	Laparoscopic sleeve gastrectomy without over-sewing of the staple line is effective and safe. Wideochirurgia I Inne Techniki Maloinwazyjne, 2014, 1, 46-52.	0.7	10
80	Glucose Control in the ICU. Journal of Diabetes Science and Technology, 2014, 8, 652-657.	2.2	6
81	The role of adipose tissue immune cells in obesity and low-grade inflammation. Journal of Endocrinology, 2014, 222, R113-R127.	2.6	409
82	The expanding role of incretin-based therapies: how much should we expect?. Journal of Endocrinology, 2014, 221, E1-E2.	2.6	0
83	Laparoscopic sleeve gastrectomy ameliorates mRNA expression of inflammation-related genes in subcutaneous adipose tissue but not in peripheral monocytes of obese patients. Molecular and Cellular Endocrinology, 2014, 383, 96-102.	3.2	37
84	Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects. Drug Safety, 2014, 37, 1003-1010.	3.2	10
85	The influence of deep hypothermia on inflammatory status, tissue hypoxia and endocrine function of adipose tissue during cardiac surgery. Cryobiology, 2014, 68, 269-275.	0.7	11
86	Triazole GHS-R1a antagonists JMV4208 and JMV3002 attenuate food intake, body weight, and adipose tissue mass in mice. Molecular and Cellular Endocrinology, 2014, 393, 120-128.	3.2	9
87	Use of Non-Invasive Parameters of Non-Alcoholic Steatohepatitis and Liver Fibrosis in Daily Practice - An Exploratory Case-Control Study. PLoS ONE, 2014, 9, e111551.	2.5	37
88	Substantially elevated C-reactive protein (CRP), together with low levels of procalcitonin (PCT), contributes to diagnosis of fungal infection in immunocompromised patients. Supportive Care in Cancer, 2013, 21, 2733-2742.	2.2	41
89	The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels. Cytokine, 2013, 64, 441-447.	3.2	19
90	Liver, but not adipose tissue PEDF gene expression is associated with insulin resistance. International Journal of Obesity, 2013, 37, 1230-1237.	3.4	22

#	Article	IF	Citations
91	Bariatric Surgery and the Mechanism of Diabetes Remission: Are We Getting There?. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4336-4338.	3.6	5
92	Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica, 2013, 98, e124-e126.	3.5	64
93	Changes in Energy Metabolism in Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1651-1658.	3.6	49
94	The Use of Continuous Glucose Monitoring Combined with Computer-Based eMPC Algorithm for Tight Glucose Control in Cardiosurgical ICU. BioMed Research International, 2013, 2013, 1-8.	1.9	42
95	Serum Preadipocyte Factor-1 Concentrations in Females with Obesity and Type 2 Diabetes Mellitus: The Influence of Very Low Calorie Diet, Acute Hyperinsulinemia, and Fenofibrate Treatment. Hormone and Metabolic Research, 2013, 45, 820-826.	1.5	18
96	Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria. International Journal of Endocrinology, 2013, 2013, 1-7.	1.5	38
97	Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGFâ€19 and FGFâ€21 in morbidly obese subjects. Obesity, 2013, 21, 1335-1342.	3.0	106
98	Does IT Bring Hope for Wellbeing?. , 2013, , 270-302.		1
99	Plasma mannose-binding lectin is stimulated by PPARÎ± in humans. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E595-E602.	3.5	20
100	Decrease in Blood Cortisol Corresponds to Weight Gain following Deep Brain Stimulation of the Subthalamic Nucleus in Parkinsonâ€™s Disease. Stereotactic and Functional Neurosurgery, 2012, 90, 410-411.	1.5	15
101	Muscle and Fat Metabolism in Obesity After Kidney Transplantation: No Effect of Peritoneal Dialysis or Hemodialysis. , 2012, 22, 166-170.		10
102	Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. Cytokine, 2012, 58, 165-168.	3.2	29
103	Serum concentrations and tissue expression of components of insulin-like growth factor-axis in females with type 2 diabetes mellitus and obesity: The influence of very-low-calorie diet. Molecular and Cellular Endocrinology, 2012, 361, 172-178.	3.2	28
104	Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. Journal of Inherited Metabolic Disease, 2012, 35, 541-548.	3.6	28
105	No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. Clinical Rheumatology, 2012, 31, 67-71.	2.2	18
106	The Effect of Very-Low-Calorie Diet on mRNA Expression of Inflammation-Related Genes in Subcutaneous Adipose Tissue and Peripheral Monocytes of Obese Patients with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E606-E613.	3.6	61
107	The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. Cytokine, 2011, 55, 116-121.	3.2	31
108	The Peptidic GHS-R antagonist [D-Lys3]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity. Molecular and Cellular Endocrinology, 2011, 343, 55-62.	3.2	40

#	Article	IF	Citations
109	Evaluating Glycemic Control Algorithms by Computer Simulations. Diabetes Technology and Therapeutics, 2011, 13, 713-722.	4.4	24
110	Endocrine function of adipose tissue and its clinical use: still waiting for the prime time?. Expert Review of Endocrinology and Metabolism, 2011, 6, 5-8.	2.4	1
111	Increasing skeletal muscle fatty acid transport protein 1 (FATP1) targets fatty acids to oxidation and does not predispose mice to diet-induced insulin resistance. Diabetologia, 2011, 54, 1457-1467.	6.3	43
112	Adipokine profile is modulated in subcutaneous adipose tissue by TNFÂ inhibitors in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 2054-2056.	0.9	9
113	Modulation of subcutaneous adipose tissue adipokines by TNF-Â blockade therapy in patients with inflammatory arthritides. Annals of the Rheumatic Diseases, 2011, 70, A85-A85.	0.9	0
114	Hormonal regulators of food intake and weight gain in Parkinson's disease after subthalamic nucleus stimulation. Neuroendocrinology Letters, 2011, 32, 437-41.	0.2	29
115	Increased proinflammatory cytokine production in adipose tissue of obese patients with chronic kidney disease. Wiener Klinische Wochenschrift, 2010, 122, 466-473.	1.9	25
116	Association of macrophage inhibitory cytokine-1 with nutritional status, body composition and bone mineral density in patients with anorexia nervosa: the influence of partial realimentation. Nutrition and Metabolism, 2010, 7, 34.	3.0	27
117	Estradiol Supplementation Helps Overcome Central Leptin Resistance of Ovariectomized Mice on a High Fat Diet. Hormone and Metabolic Research, 2010, 42, 182-186.	1.5	28
118	Expression of adipokines and estrogen receptors in adipose tissue and placenta of patients with gestational diabetes mellitus. Molecular and Cellular Endocrinology, 2010, 314, 150-156.	3.2	90
119	Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1410-1411.	0.9	94
120	Clinical Evaluation of Subcutaneous Lactate Measurement in Patients after Major Cardiac Surgery. International Journal of Endocrinology, 2009, 2009, 1-8.	1.5	4
121	Diabetes management in OLDES project. , 2009, 2009, 7228-31.		7
122	Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis: Figure 1. Annals of the Rheumatic Diseases, 2009, 68, 295-296.	0.9	112
123	The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation. Journal of Lipid Research, 2009, 50, 1068-1079.	4.2	50
124	Enhanced Expressions of mRNA for Neuropeptide Y and Interleukin 1 Beta in Hypothalamic Arcuate Nuclei during Adjuvant Arthritis-Induced Anorexia in Lewis Rats. NeuroImmunoModulation, 2009, 16, 377-384.	1.8	15
125	Comparison of Three Protocols for Tight Glycemic Control in Cardiac Surgery Patients. Diabetes Care, 2009, 32, 757-761.	8.6	90
126	Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. European Journal of Endocrinology, 2009, 161, 397-404.	3.7	135

#	Article	IF	Citations
127	Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease. Nutrition, 2009, 25, 762-768.	2.4	74
128	The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clinical Immunology, 2009, 133, 157-170.	3.2	345
129	Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factorâ€21 in patients with type 2 diabetes and obesity. Clinical Endocrinology, 2009, 71, 369-375.	2.4	245
130	The use of microdialysis to characterize the endocrine production of human subcutaneous adipose tissue in vivo. Regulatory Peptides, 2009, 155, 156-162.	1.9	13
131	Laparoscopic Sleeve Gastrectomy without an Over-Sewing of the Staple Line. Obesity Surgery, 2008, 18, 1257-1262.	2.1	81
132	Comparison of Manual and Automatic (MagNA Pure) Isolation Methods of Total RNA from Adipose Tissue. Molecular Biotechnology, 2008, 38, 195-201.	2.4	5
133	Adrenocortical changes and arterial hypertension in lipoatrophic A-ZIP/F-1 mice. Molecular and Cellular Endocrinology, 2008, 280, 39-46.	3.2	16
134	The endocrine profile of subcutaneous and visceral adipose tissue of obese patients. Molecular and Cellular Endocrinology, 2008, 291, 63-70.	3.2	75
135	Asymmetric Dimethylarginine in Obesity After Renal Transplantation. , 2008, 18, 513-520.		9
136	Asymmetric Dimethylarginine and Adiponectin After Renal Transplantation: Role of Obesity. , 2008, 18, 154-157.		11
137	OLDES: New solution for long-term diabetes compensation management. , 2008, 2008, 4346-9.		5
138	Plasma Concentrations of Fibroblast Growth Factors 19 and 21 in Patients with Anorexia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3627-3632.	3.6	100
139	Blood Glucose Control by a Model Predictive Control Algorithm with Variable Sampling Rate Versus a Routine Glucose Management Protocol in Cardiac Surgery Patients: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2960-2964.	3.6	98
140	3.221 Hormonal dysregulation contributes to weight gain after DBS STN in Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S167.	2.2	0
141	Changes of endocrine function of adipose tissue in anorexia nervosa: comparison of circulating levels versus subcutaneous mRNA expression. Clinical Endocrinology, 2007, 67, 674-678.	2.4	58
142	Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine, 2006, 35, 247-252.	3.2	141
143	Effect of cholecystokinin on feeding is attenuated in monosodium glutamate obese mice. Regulatory Peptides, 2006, 136, 58-63.	1.9	24
144	Leptinaemia and Antiendothelial Antibodies in Accelerated Atherosclerosis - Is There a Relationship?. Vascular Disease Prevention, 2006, 3, 265-268.	0.2	0

#	Article	IF	Citations
145	Improvement of Insulin Sensitivity after Peroxisome Proliferator-Activated Receptor-Î± Agonist Treatment Is Accompanied by Paradoxical Increase of Circulating Resistin Levels. Endocrinology, 2006, 147, 4517-4524.	2.8	62
146	Increased Subcutaneous and Epicardial Adipose Tissue Production of Proinflammatory Cytokines in Cardiac Surgery Patients: Possible Role in Postoperative Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4620-4627.	3.6	223
147	Multicentric, Randomized, Controlled Trial to Evaluate Blood Glucose Control by the Model Predictive Control Algorithm Versus Routine Glucose Management Protocols in Intensive Care Unit Patients: Response to Ligtenberg et al.. Diabetes Care, 2006, 29, 1987-1988.	8.6	16
148	Multicentric, Randomized, Controlled Trial to Evaluate Blood Glucose Control by the Model Predictive Control Algorithm Versus Routine Glucose Management Protocols in Intensive Care Unit Patients. Diabetes Care, 2006, 29, 271-276.	8.6	189
149	Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Annals of the Rheumatic Diseases, 2006, 66, 458-463.	0.9	226
150	Clinical Evaluation of Alternative-Site Glucose Measurements in Patients After Major Cardiac Surgery. Diabetes Care, 2006, 29, 1275-1281.	8.6	46
151	Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3Bâ€“null mice. Journal of Clinical Investigation, 2006, 116, 3240-3251.	8.2	156
152	The role of resistin in obesity-induced insulin resistance. Current Opinion in Investigational Drugs, 2006, 7, 306-11.	2.3	28
153	Serum Adiponectin and Resistin Concentrations in Patients with Restrictive and Binge/Purge Form of Anorexia Nervosa and Bulimia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1366-1370.	3.6	103
154	Plasma levels of active and total ghrelin in renal failure: A relationship with GH/IGF-I axis. Growth Hormone and IGF Research, 2005, 15, 369-376.	1.1	31
155	Adiponectin and its potential in the treatment of obesity, diabetes and insulin resistance. Current Opinion in Investigational Drugs, 2005, 6, 988-93.	2.3	22
156	Peroxisome Proliferator-Activated Receptor-Î± Deficiency Does Not Alter Insulin Sensitivity in Mice Maintained on Regular or High-Fat Diet: Hyperinsulinemic-Euglycemic Clamp Studies. Endocrinology, 2004, 145, 1662-1667.	2.8	42
157	Genetic Background (C57BL/6J Versus FVB/N) Strongly Influences the Severity of Diabetes and Insulin Resistance in ob/ob Mice. Endocrinology, 2004, 145, 3258-3264.	2.8	171
158	Increased Insulin Sensitivity in PaternalGnasKnockout Mice Is Associated with Increased Lipid Clearance. Endocrinology, 2004, 145, 4094-4102.	2.8	79
159	Soluble Leptin Receptor and Leptin Levels in Pregnant Women Before and After Delivery. Endocrine Research, 2004, 30, 379-385.	1.2	14
160	Muscle-Specific Overexpression of CD36 Reverses the Insulin Resistance and Diabetes of MKR Mice. Endocrinology, 2004, 145, 4667-4676.	2.8	53
161	Changes of Noradrenergic Activity and Lipolysis in the Subcutaneous Abdominal Adipose Tissue of Hypoâ€•and Hyperthyroid Patients: An In Vivo Microdialysis Study. Annals of the New York Academy of Sciences, 2004, 1018, 541-549.	3.8	24
162	Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia, 2004, 47, 2215-2225.	6.3	37

#	Article	IF	Citations
163	Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1â€“deficient mice. Journal of Clinical Investigation, 2004, 113, 96-105.	8.2	131
164	Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1â€“deficient mice. Journal of Clinical Investigation, 2004, 113, 96-105.	8.2	200
165	Liver Peroxisome Proliferator-activated Receptor Î³ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass. Journal of Biological Chemistry, 2003, 278, 34268-34276.	3.4	672
166	Insulin Resistance in the Liver-Specific IGF-1 Gene-Deleted Mouse Is Abrogated by Deletion of the Acid-Labile Subunit of the IGF-Binding Protein-3 Complex. Diabetes, 2003, 52, 2483-2489.	0.6	89
167	Opposite Effects of Background Genotype on Muscle and Liver Insulin Sensitivity of Lipoatrophic Mice. Journal of Biological Chemistry, 2003, 278, 3992-3999.	3.4	50
168	Peroxisome Proliferator-Activated Receptor-Â Agonist Treatment in a Transgenic Model of Type 2 Diabetes Reverses the Lipotoxic State and Improves Glucose Homeostasis. Diabetes, 2003, 52, 1770-1778.	0.6	173
169	Differential Effects of Rosiglitazone on Skeletal Muscle and Liver Insulin Resistance in A-ZIP/F-1 Fatless Mice. Diabetes, 2003, 52, 1311-1318.	0.6	87
170	Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3445-3449.	7.1	487
171	Cutaneous Trematode Collyriclum faba in Wild Birds in the Central European Carpathians. Journal of Parasitology, 2003, 89, 412-416.	0.7	22
172	Effects of Hypo- and Hyperthyroidism on Noradrenergic Activity and Glycerol Concentrations in Human Subcutaneous Abdominal Adipose Tissue Assessed with Microdialysis. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5605-5608.	3.6	48
173	Liver-specific disruption of PPARÎ³ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. Journal of Clinical Investigation, 2003, 111, 737-747.	8.2	292
174	Liver-specific disruption of PPARÎ³ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. Journal of Clinical Investigation, 2003, 111, 737-747.	8.2	498
175	SOLUBLE LEPTIN RECEPTOR LEVELS IN PATIENTS WITH ANOREXIA NERVOSA. Endocrine Research, 2002, 28, 199-205.	1.2	23
176	PLASMA GHRELIN LEVELS IN PATIENTS WITH SHORT BOWEL SYNDROME. Endocrine Research, 2002, 28, 27-33.	1.2	53
177	Adrenalectomy Improves Diabetes in A-ZIP/F-1 Lipoatrophic Mice by Increasing Both Liver and Muscle Insulin Sensitivity. Diabetes, 2002, 51, 2113-2118.	0.6	42
178	WY14,643, a Peroxisome Proliferator-activated Receptor Î± (PPARÎ±) Agonist, Improves Hepatic and Muscle Steatosis and Reverses Insulin Resistance in Lipoatrophic A-ZIP/F-1 Mice. Journal of Biological Chemistry, 2002, 277, 24484-24489.	3.4	171
179	Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. Journal of Human Hypertension, 2002, 16, 41-45.	2.2	39
180	THE CHANGES OF SERUM LEPTIN AND SOLUBLE LEPTIN RECEPTOR LEVELS IN PATIENTS UNDERGOING MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS BEFORE AUTOLOGOUS STEM CELLS TRANSPLANTATION. Endocrine Research, 2002, 28, 189-197.	1.2	3

#	Article	IF	Citations
181	The role of dopamine in methylene blue-mediated inhibition of estradiol benzoate-induced anterior pituitary hyperplasia in rats. Neuroscience Letters, 2001, 304, 194-198.	2.1	4
182	THE INFLUENCE OF SHORT-TERM FASTING ON SERUM LEPTIN LEVELS, AND SELECTED HORMONAL AND METABOLIC PARAMETERS IN MORBIDLY OBESE AND LEAN FEMALES. Endocrine Research, 2001, 27, 251-260.	1.2	24
183	Leptin as an Acute Phase Reactant after Non-Adjustable Laparoscopic Gastric Banding. Obesity Surgery, 2001, 11, 609-614.	2.1	24
184	Serum leptin levels in patients with hyperlipidemias. Nutrition, 2000, 16, 429-433.	2.4	26
185	Interaction Between Serum Leptin Levels and Hypothalamo-Hypophyseal-Thyroid Axis in Patients with Anorexia Nervosa. Endocrine Research, 2000, 26, 219-230.	1.2	27
186	Relationship of serum leptin levels and selected nutritional parameters in patients with protein-caloric malnutrition. Nutrition, 1999, 15, 829-833.	2.4	37
187	Treatment with the No-Synthase Inhibitor, Methylene Blue, Moderates the Decrease in Serum Leptin Concentration in Streptozotocin-Induced Diabetes. Endocrine Research, 1999, 25, 163-171.	1.2	10
188	Lower serum leptin concentrations in rugby players in comparison with healthy non-sporting subjects ? relationships to anthropometric and biochemical parameters. European Journal of Applied Physiology, 1998, 79, 58-61.	2.5	18
189	Estrogenic effect of estradiol-sulfamate on the male rat anterior pituitry. Journal of Steroid Biochemistry and Molecular Biology, 1998, 67, 359-362.	2.5	4
190	Comparison ofin vivolong - term treatment of rats by methylene blue with itsin vitroeffects on thyroid hormone - nuclear receptor complex formation in liver. Endocrine Research, 1997, 23, 157-165.	1.2	1
191	An increase in the blood thyroxine level after methylene blue in rats: The interaction with carbimazole. Endocrine Research, 1995, 21, 709-717.	1.2	5